Catalyst

Slingshot members are tracking this event:

Celgene (CELG) Announces Phase 1b Top-Line Data From CD-001 Evaluating GED-0301 in Patients with Active Crohn's Disease

Source Link:
http://ir.celgene.com/releasedetail.cfm?ReleaseID=981642

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
CELG
100%
GLPG
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details "Galapagos NV is up on modestly higher volume in early trading. The bullish action is being stoked by increased optimism with Crohn's disease (CD) candidate filgotinib after Celgene  released early-stage data on its CD candidate GED-0301."
http://seekingalpha....
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
Oct 16, 2016
Occurred Source:
http://ir.celgene.com/releasedetail.cfm?ReleaseID=993756
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Endoscopy Trial, Cd-001, Ged-0301, Crohn's Disease
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.